C
Cornfeld Mark J
Researcher at GlaxoSmithKline
Publications - 8
Citations - 269
Cornfeld Mark J is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Enzalutamide & Tolerability. The author has an hindex of 4, co-authored 8 publications receiving 228 citations. Previous affiliations of Cornfeld Mark J include Research Triangle Park & Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Anthony W. Tolcher,Amita Patnaik,Kyriakos P. Papadopoulos,Drew W. Rasco,Carlos Becerra,Alicia J. Allred,Keith W. Orford,Gursel Aktan,Geraldine Ferron-Brady,Nageatte Ibrahim,Jennifer Gauvin,Monica Motwani,Cornfeld Mark J +12 more
TL;DR: Continuous daily dosing of trametinib/afuresertib combination was poorly tolerated; further study of intermittent dose schedule or combination of tramETinib with more selective inhibitors may be warranted.
Journal ArticleDOI
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Juneko E. Grilley-Olson,Philippe L. Bedard,Angelica Fasolo,Cornfeld Mark J,Cornfeld Mark J,Cornfeld Mark J,Leanne Cartee,Leanne Cartee,Albiruni Ryan Abdul Razak,Lee-Anne Stayner,Yuehui Wu,Yuehui Wu,R. Greenwood,R. Greenwood,R. Greenwood,Rajeshwar Singh,Rajeshwar Singh,Carrie B. Lee,Johanna C. Bendell,H. A. Burris,G. Del Conte,Cristiana Sessa,J. R. Infante +22 more
TL;DR: GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities, which may be due to overlapping toxicities precluding sufficient dose exposure.
Journal ArticleDOI
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
Gary R. Hudes,Scott T. Tagawa,Young E. Whang,Ming Qi,Xiang Qin,Thomas A. Puchalski,Manjula Reddy,Cornfeld Mark J,Cornfeld Mark J,Mario A. Eisenberger +9 more
TL;DR: It is suggested that siltuximab in combination with docetaxel is safe and shows preliminary efficacy in patients with CRPC, although alternative siltUXimab schedules may be better tolerated for future studies.
Journal ArticleDOI
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J. Arceci,Carl E. Allen,Ira J. Dunkel,Eric D. Jacobsen,James A. Whitlock,Robert Vassallo,Shannon R. Morris,Shannon R. Morris,Alison Portnoy,Beth Ann Reedy,Deborah A. Smith,Deborah A. Smith,Robert B. Noble,Amy A. Murnane,Cornfeld Mark J,Carlos Rodriguez-Galindo,Mark L. Heaney,Mark L. Heaney,Kenneth L. McClain,Sarah R. Vaiselbuh +19 more
TL;DR: A clinical response in an adult patient with Langerhans cell histiocytosis participating in the first‐in‐human trial of afuresertib prompted this prospective trial.
Patent
Enzalutamide in combination with afuresertib for the treatment of cancer
TL;DR: A combination of androgen receptor inhibition and AKT inhibition is considered in this article, where the authors propose a novel combination comprising an androgen inhibitor and an AKT inhibiting compound, for example: N -{(1S)-2-amino-1]-1-[(3-fluorophenyl)methyl]ethyl}-5- chloro-4-(4-chloro-1-methyl-1H-pyrazol-5]-2-thiophenecarboxamide, and optional additional antineoplastic agents.